von Felden J, et al. - Authors investigated the efficacy and safety of sofosbuvir/velpatasvir (SOF/VEL) ± ribavirin (RBV), as well as the consequence of nonstructural protein 5A (NS5A) resistance-associated substitutions (RASs) and RBV use on the treatment outcome in hepatitis C virus (HCV) genotype 3 (GT3) infection in patients from 10 treatment centres across Germany. Findings demonstrated the safety and high efficacy of 12 weeks of SOL/VEL ± RBV in HCV GT3 across a diverse patient cohort. The presence of baseline NS5A RASs was a rare occurrence and it did not influence SVR, irrespective of the use of RBV.